Search clinical trials for: Sofosbuvir, Sovaldi

Total 367 results

Federal University of São Paulo

Completed

Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)

Hepatitis C, Chronic

Brazil
Mohamed Saad

Unknown

Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C

HCV Infection

Egypt
Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
Genuine Research Center, Egypt
Al-debeiky pharma

Completed

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Healthy

Egypt
Genuine Research Center, Egypt
Magic Pharma, Egypt

Completed

A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Healthy

Egypt
Assiut University

Recruiting

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

Hepatitis C, Chronic

Egypt
Assiut University

Not yet recruiting

the Pulmonary Safety of Antihepatitis C Treatment

Hepatitis C
Sunshine Lake Pharma Co., Ltd.

Completed

Phase 3 Study of Yimitasvir Phosphate Capsules

Chronic HCV Infection

China
Hannover Medical School
Gilead Sciences; HepNet Study House, German Liverfoundation; German Center for...

Completed

HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)

Hepatitis E | Hepatitis Chronic Viral

Germany
Sunshine Lake Pharma Co., Ltd.

Completed

Phase 2 Study of Yimitasvir Phosphate Capsules

Chronic HCV Infection

China
Genuine Research Center, Egypt
Multi-Apex Pharma

Completed

A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)

Healthy

Egypt
Tanta University

Unknown

Sofosbuvir in Treatment of COVID 19

COVID

Egypt
Gilead Sciences

Completed

Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea

Hepatitis C Virus

Korea, Republic of
MassBiologics

Terminated

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C (MBL-HCV1)

Hepatitis C Infection

United States
Ginkgopharma CO., LTD

Unknown

Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients

Hepatitis C Virus Infection

China
Gilead Sciences

Completed

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

HCV Infection

Mexico
Ain Shams University

Unknown

Metabolic Changes in Chronic HCV Patients Receiving DAAS (HCV DAAS)

Chronic Hepatitis C

Egypt
Genuine Research Center, Egypt
Pharmed Healthcare, Egypt

Completed

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Healthy

Egypt
Ginkgopharma CO., LTD

Unknown

Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients

Hepatitis C Virus Infection

China
Ain Shams University
Cairo University

Recruiting

Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

HCV

Egypt
University of Texas Southwestern Medical Center
Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University

Terminated

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study (Optimal)

Liver Disease

United States
FixHepC

Unknown

Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods (REDEMPTION)

Hepatitis C

Australia
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India

Hepatitis C Virus

India
Eman Sayed Hassan Abd Allah

Unknown

Hepatitis c and Vitamin D and Iron Status (hepatitisc)

Hepatitis C
Sherief Abd-Elsalam
Benha University

Unknown

Effect of Direct-acting Antiviral Drugs on Erectile Function

Hepatitis C

Egypt
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis (VALOR-HCV)

Hepatitis C Virus Infection

United States
Humanity and Health Research Centre
Beijing 302 Hospital

Completed

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

Chronic Hepatitis C Infection

China
Kirby Institute

Completed

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)

Hepatitis C

Australia, New Zealand
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

HCV Infection

New Zealand, United States, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection

Chronic HCV Infection

India
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Hepatitis C | Cirrhosis | Portal Hypertension | With or Without Liver Decompensation

United States, Spain, New Zealand, Australia, France
University of California, San Francisco
Janssen Scientific Affairs, LLC

Withdrawn

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

Hepatitis C, Chronic | HIV CDC Category A1

United States
Sherief Abd-Elsalam

Unknown

Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C

Hepatitis C

Egypt
University of Maryland, Baltimore
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection (APOSTLE)

Hepatitis B

United States
Kirby Institute

Completed

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. (REACT)

Hepatitis C

Australia, United States, United Kingdom, New Zealand, Switzerland, Canada, Germany, Netherlands
Tarek I. Hassanein, M.D., FACP, FAG, AGAF

Completed

Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

Hepatitis C | Cirrhosis

United States
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Hepatitis C Virus

Egypt
Gilead Sciences

Completed

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Chronic Hepatitis C | Human Immunodeficiency Virus

France, Italy, United Kingdom, Germany, Spain, Australia
Arrowhead Regional Medical Center

Unknown

Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

Hepatitis C

United States
Gilead Sciences

Completed

Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Hepatitis C Virus

United States
University of Colorado, Denver
Janssen Scientific Affairs, LLC

Terminated

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

Hepatitis C

United States
Gilead Sciences

Completed

Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Hepatitis C

Russian Federation
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Hepatitis C | Human Immunodeficiency Virus

United States, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Hepatitis C Virus

United States, Puerto Rico
Beni-Suef University

Completed

Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Chronic Hepatitis C Virus Infection
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection

Hepatitis C

Japan
Beni-Suef University

Completed

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Chronic Hepatitis C Virus Infection
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
Gilead Sciences

Completed

Phase 3 Study of Sofosbuvir and Ribavirin (FISSION)

Hepatitis C

United States, Australia, Canada, Puerto Rico, New Zealand, Sweden, Italy, Netherlands
Tanta University

Unknown

Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

Covid19

Egypt

3

Subscribe